IAP10 Rec'd PCT/PTO 09 DEC 2005

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731062905 US

December 9, 2005

Express Mail Label Number

Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER (REV 10-96) 4-33201A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 10/560322 **CONCERNING A FILING UNDER 35 U.S.C. 371** PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 18 June 2004 30 June 2003 PCT/EP04/006625 TITLE OF INVENTION PROTON-SENSING G-PROTEIN COUPLED RECEPTORS AND DNA SEQUENCES THEREOF APPLICANT(S) FOR DO/EO/US BAUMGARTEN, ET AL. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. a.
is transmitted herewith (required only if not transmitted by the International Bureau). b. Mas been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 11. 📙 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A change of power of attorney and/or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 17. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4). 19. Other items or information: Unexecuted Declaration

IAP9 Rec'd PCT/PTO 09 DEC 2005

U.S. APPLICATION NO (if know)					4-33201/A	TORNEY'S DOCKET NUMBER 33201/A				
The following fees are submitted:							CALCULATIONS PTO USE			
							ONLY			
21. Dasic national fee										
22. Examination Fee										
 If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$ 										
\cdot , ,										
데 All other situations \$200										
·23. Search fee										
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international										
application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$400										
All other situations										
TOTAL OF 24 22 AND 22 -								900		
TOTAL OF 21, 22 AND 23 = Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing)										
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.										
Total Sheets Ext		er of each addition f (round up to a w		n	RA	TE				
77	/50 =	(lould up to a w	noie namber)	X	\$	250	\$. 0		
Surcharge of \$ f	or furnishing the oath	of declaration late	erthan □ a	3O			\$			
months from the earliest claimed priority date (37 CFR 1.492(e)).										
CLAIMS Total claims	NUMBER FILE	<u> 20 = NUMBE</u>	R EXTRA	X	RATI	<u>5</u> 0	\$			
Independent claims	3	-3 =	0	X	\$	200	\$	0		
MULTIPLE DEPENDE	NT CLAIM(S) (if app		05.450\/5	+	\$	360	\$			
TOTAL OF ABOVE CALCULATIONS = Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be							\$	0		
filed (Note 37 CFR 1.9, 1.27, 1.28).							\$			
SUBTOTAL =							\$	900		
Processing fee of \$ for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$			
TOTAL NATIONAL FEE =							\$	900		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$ per property +							\$			
TOTAL FEES ENCLOSED =							\$	900		
								ount to	\$	
								funded	•	
a. A check in the amount of \$ to cover the above fees is enclosed.									φ	
b. 🖂 Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 cover the above fees. A duplicate copy of this form is enclosed.										
c. 🗵 The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
			Paul	J. Pagli						
Novartis	II a Akrael Day		Atto	ney for a	Applica	nts				
Corporate Intellectual Property Reg. No. 52,498 One Health Plaza, Building 104 (617) 871-3343										
East Hanover, Dated: Decem	NJ 07936-1080 nber 9, 2005		•							